CARN Practice Exam – Comprehensive Study Guide 2026

Tranylcypromine is classified as a monoamine oxidase inhibitor (MAOI). This type of medication works by inhibiting the action of monoamine oxidase, an enzyme responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. By blocking this enzyme, MAOIs increase the availability of these neurotransmitters, which can help alleviate symptoms of depression and anxiety.

The specific mechanism of MAOIs is crucial in treating certain mood disorders, especially when other classes of antidepressants have failed. It is important to note that patients taking MAOIs must adhere to dietary restrictions to avoid potentially dangerous interactions with certain foods that contain tyramine.

In contrast, selective serotonin reuptake inhibitors (SSRIs) primarily target serotonin reuptake to increase serotonin levels and are a different class of antidepressants. Beta-blockers are commonly used to manage cardiovascular conditions and anxiety but do not function as antidepressants. Tricyclic antidepressants (TCAs) work by inhibiting the reuptake of norepinephrine and serotonin, but they operate through a different mechanism than MAOIs. Therefore, Tranylcypromine's classification as a monoamine oxidase inhibitor is accurate and aligns with